Amiselimod, also known as MT1303, is a potent and selective immunosuppressant and sphingosine 1 phosphate receptor modulator. Amiselimod may be potentially useful for treatment of multiple sclerosis; inflammatory diseases; autoimmune diseases; psoriasis and inflammatory bowel diseases. Amiselimod is currently being developed by Mitsubishi Tanabe Pharma Corporation.
仅供研究使用。 我们不向患者出售。
化学信息
名称 | Amiselimod HCl |
Iupac 化学名称 | Amiselimod HCl |
同义词 | MT-1303; MT1303; MT 1303 |
英文同义词 | MT-1303; MT1303; MT 1303 |
分子式 | C19H31ClF3NO3 |
分子量 | 413.91 |
InChiKey | |
InChi | |
Cas号 | 942398-84-7 |
相关CAS号 | |
外观性状 | crystalline solid |
纯度 | 98% |
存储 | 3 years -20ºCpowder |
可溶性 | Soluble in DMSO |
处理方式 | |
运输条件 | Shipped under ambient temperature as non-hazardous chemical. |
海关编码 | |
Targets | |
Mechanism | |
Cell study | |
Animal study | |
Clinical study | |